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Quo usque tandem abutere, Catilina, patientia nostra?
“How much longer, Catilina, will you try our patience?” [1]
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The thorough study of the SAPALDIA cohort by Walther et
al. [2] on prevalence and guideline adherence in a popula-
tion of Swiss hypertensive patients is devastating testimony
to the current state of antihypertensive therapy in Switzer-
land.
Of the 1866 patients with hypertension, the authors docu-
mented that a full 50% were not aware of their disease. This
is a stunning number for the 21st century in Switzerland;
it is reminiscent of what is currently observed in so-called
developing countries or was observed in other westernised
countries such as the USA and the UK decades ago. Phys-
icians of course may argue that if patients are not known
to have hypertension they simply have never seen a doc-
tor who diagnosed and treated the disease. However, this
brings us to the most striking number in the SAPALDIA
cohort. Of all patients with doctor-diagnosed hypertension,
more than half, i.e. 60%, were uncontrolled – uncontrolled
being defined by the rather generous criterion of blood
pressure ≥140/90 mm Hg. This reflects an exorbitant de-
gree of either patients’ nonadherence to therapy or, worse,
physicians’ inertia in initiating, up-titrating and combining
antihypertensive therapy. There is little, if any, excuse in
failing to do so since in this day and age antihypertensive
therapy is simple, efficacious, safe and, by and large, free
of adverse effects. However, both patients and physicians
often do their best and go out of their way to find excuses
not to have to treat (table 1). Most patients, when properly
informed that therapy does not serve to lower blood pres-
sure only, but also the risk of the most devastating complic-
ation, namely a cerebrovascular insult, are more than will-
ing to put up with taking medication. Both physician and
patient have to come to grips with the simple fact that hy-
pertension therapy means a pill or two a day, every day, 365
days a year for the remainder of their days.
The second hard-to-swallow finding in the study of the
SAPALDIA cohort by Walther et al. [2] is how badly some
physicians are treating their patients. A full quarter of sur-
veyed patients were treated with beta-blocker monother-
apy. Can we make it clear, once and for all, that uncom-
plicated hypertension is now not or no longer an acceptable
indication for first line beta-blockade [3]? Inefficacy of
beta-blockers was documented almost 20 years ago [4].
Beta-blockers are known to have a pseudo-antihypertens-
ive effect, lowering brachial blood pressure similarly to
other antihypertensive drugs, but leaving aortic blood pres-
sure unchanged. A seemingly normal brachial blood pres-
sure deceives physicians and patients alike, yet with heart
rate lowering aortic blood pressure increases, and the risk
of heart attack and stroke remains unchanged [5, 6]. This
is not to speak of the fact that beta-blockers belong to the
least well-tolerated drug class. We have calculated that for
every stroke or heart attack prevented, three patients were
made impotent by beta-blockers and eight experienced fa-
tigue to such an extent that they stopped treatment – hardly
an acceptable risk-benefit ratio for a completely asympto-
matic disease such as mild essential hypertension [7]. Not
much better was the prescription pattern with regard to co-
morbidities in hypertension [2]. Only about one third of
Table 1: Common excuses for not treating or failure to adjust treatment even when BP in physician’s office is found to be elevated.
Patient’s and physician’s excuses Facts
“I didn’t take the pill this morning” Good antihypertensive therapy provides blood pressure control exceeding 24 hours
“My mother-in-law is visiting” Good antihypertensive therapy controls blood pressure even in stressful situations
“I just walked up the stairs to your office” Good antihypertensive therapy controls blood pressure even when exercising
“Blood pressure a little high today, you must be nervous” White coat hypertension is not an innocent condition
“Last night I was not sleeping well, snoring, waking up often” Obstructive sleep apnoea is a common cause for secondary hypertension
“My blood pressure at home is always normal” 24-hour ambulatory blood pressure monitoring will help to confirm need for treatment
“Last evening I ate Bernerplatte with lard and choucroute” A one-time high salt intake has no effect on blood pressure
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guideline nonadherence could be explained by the presen-
ce of comorbidities and about 20% of treated patients with
asthma still received beta-blockers for hypertension.
Only with hesitation do we explore the potential repercus-
sions of inappropriate antihypertensive therapy in Switzer-
land. In the ASCOT study, amlodipine-based therapy re-
duced stroke by 33% compared with atenolol-based ther-
apy, but erectile dysfunction was 22% higher with atenolol,
p >0.001 for both. Yes, blood pressure is reduced with aten-
olol and so is erectile power. But no, the risk of stroke
and heart attack persists unchanged. Is there any reason
why for many years Swiss men should suffer from erectile
dysfunction while continuing to be at an excessive risk
of suffering a stroke? And perhaps even more pertinent
is the simple question of how many strokes and heart at-
tacks could have been prevented with proper antihypertens-
ive therapy in the Swiss population over the past few dec-
ades. It seems that many physicians are convinced that they
know how to treat high blood pressure simply because they
have done so for decades. Unfortunately this amounts to
what has been called eminence-based medicine, which is
defined as “making the same mistakes with increasing con-
fidence over an impressive number of years” [8].
Physicians in Switzerland can and will have to do better.
We repeat that this day and age antihypertensive therapy is
simple, efficacious, safe and by and large free of adverse
effects. All it takes to get there is to now and then brush up
your knowledge on modern treatment or, if you are unwill-
ing or unable to do so, to refer your patient to an appropri-
ate special centre. Muddling along or “weiterwursteln” as
has been documented in the study by Walther et al. [2] is
no longer an acceptable option.
Apologies to Marcus Tullius Cicero for paraphrasing his
famous dictum, but as of now the question stands: Quo
usque tandem abutimini, medici, aegrotis nostris? “How
much longer, physicians, will you try our patients?”
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